Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL387741

CC(C)c1noc(N2CCC(COc3ccc(-c4ccc(S(=O)(=O)NCCCN5CCOCC5)cc4)cc3)CC2)n1.O=C(O)C(F)(F)F

nearest known ligand 0.55

Full drug profile on Sugi Atlas →

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 5/20 0.55
GPR183 P32249 1/20 0.55
POLB P06746 4/20 0.43
NPSR1 Q6W5P4 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
CACNA1B Q00975 1/20 0.41
ALDH1A1 P00352 1/20 0.41
TP53 P04637 1/20 0.41
GLA P06280 1/20 0.41
MAPK1 P28482 1/20 0.41
HTR7 P34969 3/20 0.39
DRD2 P14416 2/20 0.39
HTR2A P28223 2/20 0.39
HTR6 P50406 2/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL384442 0.96 GPR119 (0.56) GPR119GPR183KMT2ACACNA1BALDH1A1
SCHEMBL871159 0.94 GPR119 (0.61) GPR119GPR183POLBNPSR1KMT2A
Trifluoroacetic Acid SCHEMBL388420 0.90 GPR119 (0.56) GPR119GPR183CACNA1B
SCHEMBL871263 0.90 GPR119 (0.63) GPR119GPR183POLBNPSR1KMT2A
Trifluoroacetic Acid SCHEMBL387344 0.89 GPR119 (0.58) GPR119GPR183CYP3A4CYP2C19
Trifluoroacetic Acid SCHEMBL388814 0.88 GPR119 (0.57) GPR119GPR183
Trifluoroacetic Acid SCHEMBL387475 0.86 GPR119 (0.55) GPR119GPR183ALDH1A1TP53
Trifluoroacetic Acid SCHEMBL388851 0.86 GPR119 (0.55) GPR119GPR183CACNA1B
SCHEMBL388443 0.84 GPR119 (0.63) GPR119GPR183ALDH1A1MAPK1
SCHEMBL2883402 0.84 GPR119 (0.63) GPR119GPR183

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077812-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS FANG JING (US) 2012-03-29 US disclosed
US-8101634-B2 Bicyclic compounds and use as antidiabetics GLAXOSMITHKLINE LLC (US) 2012-01-24 US disclosed
EP-2325182-A1 Bicyclic compounds and use as antidiabetics Glaxosmithkline LLC (US) 2011-05-25 EP disclosed
US-20100029650-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS SMITH KLINE BEECHAM CORPORATION a corporation 2010-02-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077812-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS GPR119, GOT2, PC GPR119 1/4885GPR183 1491/4885POLB 1913/4885
US-20100029650-A1 BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS GPR119, GOT2, PC GPR119 1/4885GPR183 1491/4885POLB 1913/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.